Author details

Full Name

Jennifer A Wargo

Affiliation

ORCID

Career Start Year

2002

Papers

304

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37420098	Using gut microorganisms to treat cancer.		2023
36166093	Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.	Clin Cancer Res	2023
38040541	Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial.	EBioMedicine	2023
37647056	Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma.	JAMA Dermatol	2023
37904958	TARO: tree-aggregated factor regression for microbiome data integration.		2023
37724990	Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome.	Clin Cancer Res	2023
37863066	Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring.	Cancer Cell	2023
37414216	Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.	Ann Oncol	2023
36778495	alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease.		2023
37468627	Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells.	Nature	2023
37465976	Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation With Response to Neoadjuvant Therapy.	Ann Surg	2023
36894629	Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.	Nature	2023
36765735	Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment.		2023
36820825	Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma.	Cancer Immunol Res	2023
37264079	Publisher Correction: Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.		2023
37138075	Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.		2023
37196631	From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer.		2023
37010038	Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management.	J Surg Oncol	2023
37451906	MAdCAM-1: a newly identified microbial 'gut check' for T cells.		2023
36627494	Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.	Nature	2023
37063829	HPV-related anal cancer is associated with changes in the anorectal microbiome during cancer development.	Front Immunol	2023
36997799	Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.	Nat Med	2023
36690875	Fucosylation of HLA-DRB1 regulates CD4 T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy.		2023
36622383	Microbiome influencers of checkpoint blockade-associated toxicity.		2023
37365438	Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy.	Nat Rev Clin Oncol	2023
36928818	Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.	Nat Med	2023
37428011	TIME for Bugs: The Immune Microenvironment and Microbes in Precancer.		2023
37509290	Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma.	Cancers (Basel)	2023
37503252	Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade.	Res Sq	2023
35120665	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.	Cell	2022
35397955	Immunotherapy response-associated Akkermansia: canary in a coal mine?	Trends in Immunology	2022
36313661	The immune landscape of undifferentiated pleomorphic sarcoma.	Front Oncol	2022
35591978	Glioma and the gut-brain axis: opportunities and future perspectives.	Neurooncol Adv	2022
36179667	Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease.	Cell	2022
35705814	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.	Nature	2022
35584646	Trust your gut when it comes to driving CARs.	Med	2022
35449306	Gut microbes as biomarkers of ICI response - sharpening the focus.	Nature Reviews Clinical Oncology	2022
36098652	The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma.	Cancer Discov	2022
35834946	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1).	Neoplasia	2022
36289334	Neoadjuvant relatlimab and nivolumab in resectable melanoma.	Nature	2022
35440726	Targeting the gut and tumor microbiota in cancer.	Nature Medicine	2022
36153116	The Microbiome in Gastrointestinal Cancers.		2022
35810190	Multi-modal molecular programs regulate melanoma cell state.	Nat Commun	2022
35426590	Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).	Ann Surg Oncol	2022
36138151	Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.	Nat Med	2022
35419587	Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.	Clin Cancer Res	2022
35537412	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.	Cancer Cell	2022
36543374	Activated B cells suppress T-cell function through metabolic competition.	J Immunother Cancer	2022
35278716	Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020.	Pract Radiat Oncol	2022
35251322	Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials.	Therapeutic Advances in Medical Oncology	2022